IRLAB Therapeutics AB (publ) (STO:IRLAB.A)
Sweden · Delayed Price · Currency is SEK 1.620
+0.046 (2.92%)
Aug 13, 2026, 5:29 PM CET
IRLAB Therapeutics AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 95.24 | 62.8 | 114.08 | 5.72 | 61.28 | 207.91 | |
Revenue Growth | -22.02% | -44.95% | 1894.46% | -90.66% | -70.53% | 51361.88% |
Gross Profit | 95.24 | 62.8 | 114.08 | 5.72 | 61.28 | 207.91 |
Selling, General & Admin | 141.37 | 145.49 | 182.47 | 181.49 | 168.39 | 112.76 |
Depreciation & Amortization Expenses | 4.24 | 4.32 | 4.58 | 4.32 | 4.78 | 3.47 |
Other Operating Expenses | 3.67 | 6.38 | 2.14 | 0.68 | 1.22 | 39.1 |
Total Operating Expenses | 149.27 | 156.19 | 189.19 | 186.49 | 174.39 | 155.33 |
Operating Income | -54.03 | -93.4 | -75.11 | -180.77 | -113.11 | 52.58 |
Interest Income | 1.47 | 1.38 | 2.46 | 3.13 | 0 | 0 |
Interest Expense | -14.36 | -17.99 | -10.48 | -0.2 | -0.3 | -0.8 |
Total Non-Operating Income (Expense) | -12.89 | -16.61 | -8.02 | 2.93 | -0.3 | -0.8 |
Pretax Income | -66.92 | -110.01 | -83.13 | -177.84 | -113.41 | 51.78 |
Net Income | -66.92 | -110.01 | -83.13 | -177.84 | -113.41 | 51.78 |
Net Income to Common | -66.92 | -110.01 | -83.13 | -177.84 | -113.41 | 51.78 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 74 | 67 | 52 | 52 | 52 | 52 |
Shares Outstanding (Diluted) | 74 | 67 | 52 | 52 | 52 | 52 |
Shares Change | 42.01% | 29.17% | - | 0.07% | 0.16% | 8.54% |
EPS (Basic) | -1.04 | -1.64 | -1.60 | -3.43 | 2.19 | 1.00 |
EPS (Diluted) | -1.04 | -1.64 | -1.60 | -3.43 | 2.19 | 1.00 |
EPS Growth | - | - | - | - | 119.00% | - |
Free Cash Flow | -90.23 | -55.22 | -65.79 | -165.14 | -145.49 | 127.93 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -1.23 | -0.82 | -1.27 | -3.18 | -2.81 | 2.47 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -56.73% | -148.73% | -65.84% | -3160.23% | -184.59% | 25.29% |
Profit Margin | -70.26% | -175.18% | -72.87% | -3109.07% | -185.07% | 24.91% |
FCF Margin | -94.74% | -87.93% | -57.67% | -2887.12% | -237.43% | 61.53% |
EBITDA | -54.03 | -93.4 | -75.11 | -180.77 | -113.11 | 56.05 |
EBITDA Margin | -56.73% | -148.73% | -65.84% | -3160.23% | -184.59% | 26.96% |
EBIT | -54.03 | -93.4 | -75.11 | -180.77 | -113.11 | 52.58 |
EBIT Margin | -56.73% | -148.73% | -65.84% | -3160.23% | -184.59% | 25.29% |